Mistakes are normally avoidable but we are not dealing with normal times or situations for any public company such as CytoDyn. I would call out a CEO who's not doing it as well as could be... but again, Dr. Pourhassan is only human and he is the ONE who has it all on the line. The times have changed and CYDY is no longer about going through the process (FDA or otherwise for a 'drug') it's about saving lives, immediately... and I cannot care about 'mistakes' impacting the pps...

In the case of CytoDyn and Leronlimab specifically right now, it should be only and all about bringing the care, help and if possible even cure to those directly impacted by COVID-19 ... it is life and death around the globe... who knew a couple of months ago just exactly how valuable CytoDyn/Leronlimab could be? I can't even begin to think how the FDA or any other gov agency could refuse or prevent fast tracking it for cancer and HIV after this. Glad to hear CytoDyn has put in the reqest fo a meeting.

I have not attached myself to this CEO/Company/Stock as I may have done with past investments but believe CytoDyn is unlike any OTC company I've been involved in before... ever... Cytodyn has real product, real operation, real potential to SAVE THE WORLD. I feel blessed to be a miniscule part of it...